160 related articles for article (PubMed ID: 32509178)
1. MARK2 enhances cisplatin resistance via PI3K/AKT/NF-κB signaling pathway in osteosarcoma cells.
Wei X; Xu L; Jeddo SF; Li K; Li X; Li J
Am J Transl Res; 2020; 12(5):1807-1823. PubMed ID: 32509178
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of MARK2 suppresses cisplatin resistance of osteosarcoma stem cells by regulating DNA damage and repair.
Xu L; Sun Z; Wei X; Tan H; Kong P; Li Z; Yang Q; Dai E; Li J
J Bone Oncol; 2020 Aug; 23():100290. PubMed ID: 32368441
[TBL] [Abstract][Full Text] [Related]
3. Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer.
Hubaux R; Thu KL; Vucic EA; Pikor LA; Kung SH; Martinez VD; Mosslemi M; Becker-Santos DD; Gazdar AF; Lam S; Lam WL
Int J Cancer; 2015 Nov; 137(9):2072-82. PubMed ID: 25907283
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.
Song L; Zhou Z; Gan Y; Li P; Xu Y; Zhang Z; Luo F; Xu J; Zhou Q; Dai F
J Cell Biochem; 2019 Jun; 120(6):9656-9666. PubMed ID: 30548308
[TBL] [Abstract][Full Text] [Related]
5. Cordycepin augments the chemosensitivity of osteosarcoma to cisplatin by activating AMPK and suppressing the AKT signaling pathway.
Li HB; Chen JK; Su ZX; Jin QL; Deng LW; Huang G; Shen JN
Cancer Cell Int; 2021 Dec; 21(1):706. PubMed ID: 34953496
[TBL] [Abstract][Full Text] [Related]
6. Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling.
Huang Z; Huang Y; He H; Ni J
Mol Med Rep; 2015 Sep; 12(3):3916-3922. PubMed ID: 26017117
[TBL] [Abstract][Full Text] [Related]
7. RLN2 Is a Positive Regulator of AKT-2-Induced Gene Expression Required for Osteosarcoma Cells Invasion and Chemoresistance.
Ma J; Huang H; Han Z; Zhu C; Yue B
Biomed Res Int; 2015; 2015():147468. PubMed ID: 26229955
[TBL] [Abstract][Full Text] [Related]
8. Activation of unfolded protein response protects osteosarcoma cells from cisplatin-induced apoptosis through NF-κB pathway.
Yan M; Ni J; Song D; Ding M; Huang J
Int J Clin Exp Pathol; 2015; 8(9):10204-15. PubMed ID: 26617729
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic gene TRIM10 confers resistance to cisplatin in osteosarcoma cells and activates the NF-κB signaling pathway.
Xi X; Bao Y; Zhou Y; Chen Y; Zhong X; Liao J; Zhou J; Xu S; Cao Z; Hu K; Hu Y; He X; Zhou L; Lin H; Wu Q
Cell Biol Int; 2021 Jan; 45(1):74-82. PubMed ID: 32997424
[TBL] [Abstract][Full Text] [Related]
10. Hexabromocyclododecane and polychlorinated biphenyls increase resistance of hepatocellular carcinoma cells to cisplatin through the phosphatidylinositol 3-kinase/protein kinase B pathway.
An J; Wang X; Guo P; Zhong Y; Zhang X; Yu Z
Toxicol Lett; 2014 Aug; 229(1):265-72. PubMed ID: 24960055
[TBL] [Abstract][Full Text] [Related]
11. Magnoflorine inhibits the malignant phenotypes and increases cisplatin sensitivity of osteosarcoma cells via regulating miR-410-3p/HMGB1/NF-κB pathway.
Wang Y; Shang G; Wang W; Qiu E; Pei Y; Zhang X
Life Sci; 2020 Sep; 256():117967. PubMed ID: 32553931
[TBL] [Abstract][Full Text] [Related]
12. LncRNA FER1L4 induces apoptosis and suppresses EMT and the activation of PI3K/AKT pathway in osteosarcoma cells via inhibiting miR-18a-5p to promote SOCS5.
Ye F; Tian L; Zhou Q; Feng D
Gene; 2019 Dec; 721():144093. PubMed ID: 31473323
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
[TBL] [Abstract][Full Text] [Related]
14. Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt.
Xu Z; Mei J; Tan Y
Int J Oncol; 2017 Jan; 50(1):93-100. PubMed ID: 27878245
[TBL] [Abstract][Full Text] [Related]
15. SNHG16 promotes osteosarcoma progression and enhances cisplatin resistance by sponging miR-16 to upregulate ATG4B expression.
Liu Y; Gu S; Li H; Wang J; Wei C; Liu Q
Biochem Biophys Res Commun; 2019 Oct; 518(1):127-133. PubMed ID: 31427084
[TBL] [Abstract][Full Text] [Related]
16. Celastrol negatively regulates cell invasion and migration ability of human osteosarcoma via downregulation of the PI3K/Akt/NF-κB signaling pathway
Yu X; Wang Q; Zhou X; Fu C; Cheng M; Guo R; Liu H; Zhang B; Dai M
Oncol Lett; 2016 Nov; 12(5):3423-3428. PubMed ID: 27900015
[TBL] [Abstract][Full Text] [Related]
17. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling.
Wang K; Zhuang Y; Liu C; Li Y
Arch Biochem Biophys; 2012 Oct; 526(1):38-43. PubMed ID: 22820099
[TBL] [Abstract][Full Text] [Related]
19. TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma.
Li C; Cai J; Ge F; Wang G
Int J Mol Med; 2018 Oct; 42(4):1799-1808. PubMed ID: 30015899
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
